Document Detail

Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
MedLine Citation:
PMID:  17302529     Owner:  NLM     Status:  MEDLINE    
Telavancin, a once-daily dosing lipoglycopeptide derived from vancomycin, has a broad-spectrum microbiologic activity against gram-positive bacteria, including vancomycin-resistant staphylococci. Telavancin displays a dual mode of action and a rapid bactericidal killing. The in vitro activity of telavancin is superior to vancomycin and comparable with, or greater than, linezolid, daptomycin and other novel lipoglycopeptides. Telavancin is effective against gram-positive pathogens in animal models of soft tissue infections and deep-seated infections including endocarditis, pneumonia and bacteremia. Clinical experience with telavancin in Phase II and III studies for complicated skin and skin structure infections have demonstrated similar efficacy and tolerability compared with standard anti-staphylococcal beta-lactams and vancomycin. Telavancin is in Phase III studies for nosocomial pneumonia. Telavancin seems to be promising as a novel agent for empiric therapy or as an alternative agent in serious infections caused by clinically important resistant gram-positive pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin intermediate-susceptible S. aureus, vancomycin-resistant S. aureus and vancomycin-resistant enterococci.
Somvadee Laohavaleeson; Joseph L Kuti; David P Nicolau
Related Documents :
19480649 - Vancomycin resistant enterococci (vre) in swedish sewage sludge.
18034209 - Typing of vancomycin-resistant enterococcus faecium strains in a cohort of patients in ...
10914659 - Vancomycin resistance and antibiotic susceptibility of enterococci in raw meat.
19338329 - Enantioselective total synthesis of (-)-napyradiomycin a1 via asymmetric chlorination o...
6501129 - In-vitro synergy testing of triple antibiotic combinations against staphylococcus epide...
18304359 - Different bacterial gene expression patterns and attenuated host immune responses are a...
9538599 - Susceptibility pattern of streptococcus pneumoniae among pre-school children in kota bh...
7544819 - Effect of mosquito age and reproductive status on melanization of sephadex beads in pla...
25380369 - Aerobic bacterial microbiota isolated from the cloaca of the european pond turtle (emys...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  16     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-16     Completed Date:  2007-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  347-57     Citation Subset:  IM    
Hartford Hospital, Center for Anti-Infective Research and Development, 80 Seymour Street, Hartford, CT 06102, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminoglycosides / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Anti-Bacterial Agents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Drug Resistance, Bacterial
Glycopeptides / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Gram-Positive Bacterial Infections / drug therapy*
Reg. No./Substance:
0/Aminoglycosides; 0/Anti-Bacterial Agents; 0/Glycopeptides; 0/telavancin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Emerging drug therapies for preventing spontaneous preterm labor and preterm birth.
Next Document:  PTI-821: sustained-release oxycodone using gel-cap technology.